Work

314P Outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC) according to BRCA and PD-L1 status

Year: 2025

Type: article

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.104886

Authors: P. Tarantino, D. Lee, J. Foldi, P.R. Soulos, C.P. Gross, T. Grinda, E. Winer, N. Lin, I. Krop, S.M. Tolaney, S. Sammons, M. Lustberg

Institutions: Dana-Farber Cancer Institute, Yale University, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Institut Gustave Roussy, Yale Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

Funders: Pfizer, Gilead Sciences, Philippe Foundation

OpenAlex ID: W4410455761

FWCI: 0.416

Cites:

Cited by: 1

Related to: 10